Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

N/A

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03648632Not ApplicableCompleted

Stereotactic Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (LAPC)

Role: lead

NCT01928524Phase 1Completed

Chemotherapy for Patients With Cancer of the Stomach

Role: lead

NCT01094444Phase 2Completed

Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis

Role: lead

NCT01020864Phase 2Withdrawn

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

Role: lead

NCT01397019Phase 2Completed

Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

Role: lead

NCT01867697Phase 2Completed

Nordic 8 - A Phase II Trial

Role: lead

NCT01042028Phase 1Terminated

A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Role: lead

NCT00660582Phase 2Completed

FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor

Role: lead

All 8 trials loaded